Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG

Rank in Stocks #19812
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Share Price
$2.13
Last synced: 2026-11-11
Market Cap
$96.48M
Change (1 day)
3.90%
Change (1 year)
16.39%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for Adagene Inc. (ADAG)
Operating Margin as of November 2026 TTM: -240.31%
According to Adagene Inc.'s latest financial reports, its current operating margin (TTM) is -240.31%. At the end of 2025 the company had an operating margin of -279.48%.
Operating Margin history for Adagene Inc. from 2018 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -240.31% -14.02%
2025 -279.48% -99.20%
2024 -34,835.42% 26,498.01%
2023 -130.97% -85.50%
2022 -903.08% 26.98%
2021 -711.18% -82.19%
2020 -3,993.68% 0.00%
2019 -3,993.68% 248.16%
2018 -1,147.09% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -99.19%
US
33.87% -100.14%
US
-116.04% -99.52%
US
25.57% -100.11%
AU
31.23% -100.13%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about Adagene Inc.'s operating margin

What is Adagene Inc.'s operating margin?

Adagene Inc.'s operating margin is -240.31%, as of Nov 2026.

What was Adagene Inc.'s operating margin in 2025?

In 2025, Adagene Inc.'s operating margin was -279.48%, compared with -34,835.42% in 2024.

How has Adagene Inc.'s operating margin changed since 2020?

From 2020 to 2025, Adagene Inc.'s operating margin was highest in 2023 (-130.97%) and lowest in 2024 (-34,835.42%).

How does Adagene Inc.'s operating margin compare with similar companies?

Adagene Inc.'s operating margin (-240.31%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.